InvestorsHub Logo
Followers 6
Posts 874
Boards Moderated 0
Alias Born 09/28/2012

Re: None

Thursday, 11/30/2023 3:29:56 PM

Thursday, November 30, 2023 3:29:56 PM

Post# of 8733
From Morgan Stanley:

"Merck: The company is recruiting in a Ph2 trial (NCT06099782) of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475AF11)"

Fortunately, approval is still at least a couple of years away.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News